ClinicalTrials.gg
Not yet recruitingNCT07710339DEACSUpdated Jul 17, 2026

Ecological Momentary Cognitive Assessment

An interventional study of Exercise and Daylong Movement in Physical Activity, Cognition and Aging, sponsored by Wake Forest University. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Wake Forest University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Study summary

The purpose of this study is to characterize the relationships between changes in cognitive functioning across the day and patterns of physical activity in older adults. Those who participate in the program will complete tests of cognition and several surveys at the start. They will then wear an activity monitor and complete four cognitive tests plus surveys per day for one week. After this week concludes, they will continue completing the surveys and cognitive tests, and will engage in one week of structured exercise at a research center and one week where they work to move throughout the day.

02

Conditions studied

  • Physical Activity
  • Cognition
  • Aging

Browse trials for

03

In context

Motor Activity

9,798 studies on the registry are indexed under Motor Activity; 1,910 are open to participants now.

This study's planned enrollment of 30 is below the median of 60 across 8,388 interventional studies indexed under Motor Activity.

Browse Motor Activity studies →

Lead sponsor

Wake Forest University is the lead sponsor of 118 studies on the registry; 7 are open to participants now.

Of its 31 completed or terminated interventional studies of FDA-regulated products, 27 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age ≥65
  • fluent in English
  • own a smartphone
  • able to provide digital
  • able to walk without assistance from others (a cane or walker is allowed)
  • low-active as defined by participating in purposeful aerobic exercise two days or less per week

Exclusion criteria

Exclusion Criteria:

  • potential neurological cofounders (stroke, seizure disorder, recent head injury or loss of consciousness)
  • diagnosis of clinical mental abnormalities (e.g., schizophrenia, bipolar disorder, Parkinson's Disease, Alzheimer's disease and related dementias)
  • any other conditions that may impact their ability to complete the ecological momentary cognitive tasks or physical activity (e.g., visual or auditory impairments, uncontrolled arthritis)
  • A score lower than 32 on the TICS-M.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Control-Exercise First

    This condition completes the control week followed by structured exercise and then moving throughout the day.

    Behavioral: Exercise · Behavioral: Daylong Movement

  • Experimental
    Control-Daylong Movement First

    This condition completes the control week followed by moving throughout the day and then exercise.

    Behavioral: Exercise · Behavioral: Daylong Movement

Interventions

  • BehavioralExercise

    During this week, participants will be encouraged to complete 5 supervised center-based aerobic exercise sessions at a moderate to vigorous intensity.

  • BehavioralDaylong Movement

    Participants will work to increase daily steps by approximately 25% while avoiding sustained periods of sitting.

06

What researchers measure

Primary outcomes

  1. Daily cognitive performance

    Average performance on ecological momentary cognitive tasks, completed up to 4 times daily: color trick (inhibition), 2-back (working memory), hand swype (task switching)

    Time frame: From start of control week to the end of participation at 3 weeks.

07

Study locations

1 site
  • Health and Exercise Sciences
    Winstom Salem, North Carolina 27109, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Apr 2027, 7 months later.

Of 5,147 non-industry interventional studies with no phase under Motor Activity, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 36. This study's planned 7 months is below that.

Counting every sponsor, half of 5,207 studies reached it within 17 months; a quarter within 7 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2026
First posted
Jul 17, 2026
StartEst.
Aug 15, 2026
Primary completionEst.
Apr 1, 2027
CompletionEst.
Apr 1, 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07710339
Responsible party
Jason Fanning (Associate Professor, Wake Forest University) — Principal investigator
First posted
Jul 17, 2026
Start date
Aug 15, 2026 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

Carter Stoke, BS
Contact
stokcm25@wfu.edu
336-758-5042

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion